(S)-(-)-1-Formyl-2-(hydroxymethyl)pyrrolidine | 55456-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (S)-(-)-1-Formyl-2-(hydroxymethyl)pyrrolidine
• 英文别名: (S)-(-)-1-formyl-2-hydroxymethylpyrrolidine；(S)-1-formyl-2-hydroxymethylpyrrolidine；S-1-formyl-2-(hydroxymethyl)pyrrolidine；(S)-1-formylprolinol；N-formyl-L-prolinol；N-formyl prolinol；(2S)-2-(Hydroxymethyl)pyrrolidine-1-carbaldehyde
• CAS: 55456-46-7
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: MIUQKALRYUVKGS-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-(-)-1-Formyl-2-(hydroxymethyl)pyrrolidine 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 N-甲基-L-脯氨醇
  参考文献：
  名称：

  Synthesis of C2-symmetrical bis-β-amino alcohols and their application in the enantioselective addition of diethylzinc to aldehydes

  摘要：

  The C-2-symmetrical bis-beta -amino alcohols 1-6 were prepared and especially attention is focused on bridges. which link the two beta -amino alcohol units. These ligands hake been applied as chiral catalysts in the asymmetric addition of diethylzinc to aldehydes. see-Alcohols have been obtained in good yields with up to 95.4%, enantiomeric excess. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01236-9
• 作为产物：
  描述：

  L-脯氨酸 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.58h， 生成 (S)-(-)-1-Formyl-2-(hydroxymethyl)pyrrolidine
  参考文献：
  名称：

  (S)-(−)-1-AMINO-2-METHOXYMETHYLPYRROLIDINE (SAMP) AND (R)-(+)-1-AMINO-2-METHOXYMETHYLPYRROLIDINE (RAMP), VERSATILE CHIRAL AUXILIARIES

  摘要：

  DOI：

  10.15227/orgsyn.065.0173

文献信息

• Organocerium additions to proline-derived hydrazones: synthesis of enantiomerically enriched amines
  作者：Scott E. Denmark、James P. Edwards、Theodor Weber、David W. Piotrowski

  DOI：10.1016/j.tetasy.2010.04.042

  日期：2010.5

  The addition of organocerium reagents (from both organolithium and organomagnesium precursors) to chiral aldehyde hydrazones prepared from 1-aminoproline derivatives has been studied. The additions proceed in good yield and high diastereoselectivity and with good nucleophile (Me, n-Bu, i-Pr, t-Bu, Ph, etc.) and substrate scope (alkyl, alkenyl and aryl). The resulting hydrazines can be converted to

  已经研究了将有机铈试剂（来自有机锂和有机镁前体）添加到由1-氨基脯氨酸衍生物制备的手性醛中。添加以高收率和高非对映选择性以及良好的亲核试剂（Me，n- Bu，i- Pr，t- Bu，Ph等）和底物范围（烷基，烯基和芳基）进行。生成的肼可通过氢解（阮内镍）的N–N键裂解或通过Li / NH 3的酰化和裂解而转化为胺。。通过改变取代基以包括更多的配位原子（氧和氮）以及去除配位原子，研究了侧链对非对映选择性的影响。带有2-甲氧基乙氧基甲基的SAMEMP助剂具有最高的非对映选择性。值得注意的是，带有简单甲基和异丁基取代基的助剂也具有很高的选择性。给出了选择性起源的假设。
• [EN] MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS POUR LE RÉCEPTEUR MAS COUPLÉ À LA PROTÉINE G ET TRAITEMENT DES TROUBLES QUI Y SONT APPARENTÉS
  申请人：ARENA PHARM INC

  公开号：WO2013070657A1

  公开（公告）日：2013-05-16

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts, solvates, and hydrates thereof that are useful in methods of treatment and alleviation of diseases and disorders of the heart, brain, kidney, immune, and reproductive system resulting from ischemia, or reperfusion subsequent to ischemia, and any downstream complication(s) related thereto. The present invention further relates to methods of treatment and alleviation of diseases and disorders of the vasculature resulting from vasoconstriction or hypertension and any downstream complication(s) resulting from elevated blood pressure and/or reduced tissue perfusion.

  本发明涉及式（I）化合物及其药用可接受的盐、溶剂和水合物，这些化合物在治疗和缓解由缺血引起的心脏、脑、肾脏、免疫系统和生殖系统的疾病和紊乱方面具有用处，或者在缺血后再灌注引起的疾病和障碍，以及与之相关的任何下游并发症。本发明还涉及治疗和缓解由血管收缩或高血压引起的血管疾病和障碍的方法，以及由高血压和/或组织灌注减少引起的任何下游并发症。
• [EN] PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLO[2,3-B]PYRIDINE CDK9 KINASE
  申请人：ABBVIE INC

  公开号：WO2014139328A1

  公开（公告）日：2014-09-18

  Disclosed are compounds of Formula (IIa), wherein R1, R2, R3A, R3B, R3C, R3D, R3E, and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds may be used as agents in the treatment of diseases, including cancer. Also provided are pharmaceutical compositions comprising one or more compounds of Formula (IIa).

  公开的是Formula (IIa)的化合物，其中R1、R2、R3A、R3B、R3C、R3D、R3E和R4如规范中所定义，并且其药用盐。这些化合物可用作治疗疾病，包括癌症的药物。还提供了包含一个或多个Formula (IIa)化合物的药物组合物。
• Formamides as Lewis Base Catalysts in S_NReactions-Efficient Transformation of Alcohols into Chlorides, Amines, and Ethers
  作者：Peter H. Huy、Sebastian Motsch、Sarah M. Kappler

  DOI：10.1002/anie.201604921

  日期：2016.8.16

  and waste‐balance (E‐factor down to 2). Chiral substrates are converted with excellent levels of stereochemical inversion (99 %→≥95 % ee). In a practical one‐pot procedure, the primary formed chlorides can be further transformed into amines, azides, ethers, sulfides, and nitriles. The value of the method was demonstrated in straightforward syntheses of the drugs rac‐Clopidogrel and S‐Fendiline.

  简单的甲酰胺催化剂可促进以苯甲酰氯为唯一试剂将醇类有效转化为烷基氯。这些亲核取代是通过亚胺基活化的醇作为中间体进行的。这种新颖的方法甚至可以在无溶剂条件下进行，其特点是具有出色的官能团耐受性，可扩展性（> 100 g）和废物平衡（电子因子低至2）。手性底物的转化具有优异的立体化学转化水平（99％→≥95％ee）。在实际的一锅法中，初步形成的氯化物可以进一步转化为胺，叠氮化物，醚，硫化物和腈。该方法的价值在药物rac ‐ Clopidogrel和S‐芬迪林。
• [EN] METHOD OF CONVERTING ALCOHOL TO HALIDE<br/>[FR] PROCÉDÉ DE CONVERSION D'UN ALCOOL EN HALOGÉNURE
  申请人：UNIV SAARLAND

  公开号：WO2016202894A1

  公开（公告）日：2016-12-22

  The present invention relates to a method of converting an alcohol into a corresponding halide. This method comprises reacting the alcohol with an optionally substituted aromatic carboxylic acid halide in presence of an N-substituted formamide to replace a hydroxyl group of the alcohol by a halogen atom. The present invention also relates to a method of converting an alcohol into a corresponding substitution product. The second method comprises: (a) performing the method of the invention of converting an alcohol into the corresponding halide; and (b) reacting the corresponding halide with a nucleophile to convert the halide into the nucleophilic substitution product.

  本发明涉及一种将醇转化为相应卤化物的方法。该方法包括在N-取代甲酰胺的存在下，将醇与可选择取代的芳香羧酸卤化物反应，以通过卤原子取代醇的羟基。本发明还涉及一种将醇转化为相应取代产物的方法。第二种方法包括：(a)执行将醇转化为相应卤化物的本发明方法；以及(b)将相应卤化物与亲核试剂反应，将卤化物转化为亲核取代产物。